Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
NCT ID: NCT00820222
Last Updated: 2019-04-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
540 participants
INTERVENTIONAL
2009-04-14
2018-03-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
NCT00320385
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
NCT01137994
Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
NCT00820924
Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2
NCT00281658
A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT00829166
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
An amendment protocol allowed subjects who were on study treatment to enroll in a Long Term Follow Up (LTFU) phase if they had evidence of clinical benefit but no local access to standard of care treatments. Subjects received study treatment until disease progression, unacceptable toxicity, or subject withdrawal. In LTFU only Adverse Events data were collected. For the LTFU the Outcome Measure "Number of participants with the indicated Grade 3 or Grade 4 Adverse Events (AEs) occurring in \>=2% of participants in either treatment arm" and "Adverse Events" were updated.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lapatinib plus capecitabine
Lapatinib 1250 mg once daily and capecitabine 2000mg/m2/day, days 1-14, every 21 days
capecitabine
oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
lapatinib
oral medication; daily dose taken once a day
Trastuzumab plus capecitabine
trastuzumab loading dose of 8mg/kg followed by 6mg/kg q3weekly infusions, and capecitabine 2500mg/m2/day, days 1-14, every 21 days
capecitabine
oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
trastuzumab
infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
capecitabine
oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
lapatinib
oral medication; daily dose taken once a day
trastuzumab
infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ECOG Performance Status 0-2;
* Histologically or cytologically confirmed HER2-positive invasive breast cancer, with Stage IV disease;
* Prior treatment with taxanes or anthracyclines is required;
* Prior treatment with other chemotherapeutic agents, trastuzumab, endocrine and radiation therapy is permitted;
* Baseline LVEF ≥ 50% and not lower than the institutional lower limit of normal;
* Concurrent treatment with bisphosphonates is permitted, however treatment must be initiated prior to the first dose of study therapy;
* Able to swallow and retain oral medications;
* Women with potential to have children must be willing to practice acceptable methods of birth control during the study;
* Normal organ and marrow function.
Exclusion Criteria
* Concurrent treatment with an investigational agent or participation in another treatment clinical trial;
* Prior therapy with lapatinib or an ErbB2 inhibitor other than trastuzumab (including but not limited to trastuzumab-DM1 and neratinib) and capecitabine;
* Known DPD deficiency;
* Concurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapy for treatment of cancer;
* History of allergic reactions attributed to compounds chemically related to lapatinib (quinazolines), capecitabine, fluorouracil or any excipients;
* Concomitant use of CYP3A4 inhibitors or inducers;
* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel;
* History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents, or other contraindication to gadolinium contrast and other known contraindication to MRI;
* Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical or psychiatric disorder that would interfere with the patient's safety or compliance to study procedures;
* have acute or currently active/requiring anti-viral therapy hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease);
* Any on-going toxicity from prior anti cancer therapy except alopecia;
* Active cardiac disease;
* Uncontrolled infection;
* History of other malignancy, unless curatively treated with no evidence of disease for at least 5 years, subjects with adequately treated DCIS or LCIS, adequately treated non-melanoma skin cancer or curatively treated in-situ cancer of the cervix are eligible;
* Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of protocol treatment;
* Pregnant or lactating females.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Goodyear, Arizona, United States
Novartis Investigative Site
Tucson, Arizona, United States
Novartis Investigative Site
Jonesboro, Arkansas, United States
Novartis Investigative Site
Anaheim, California, United States
Novartis Investigative Site
Greenbrae, California, United States
Novartis Investigative Site
Sacramento, California, United States
Novartis Investigative Site
Santa Barbara, California, United States
Novartis Investigative Site
Washington D.C., District of Columbia, United States
Novartis Investigative Site
Boca Raton, Florida, United States
Novartis Investigative Site
Coral Springs, Florida, United States
Novartis Investigative Site
Hollywood, Florida, United States
Novartis Investigative Site
Warrenville, Illinois, United States
Novartis Investigative Site
Metairie, Louisiana, United States
Novartis Investigative Site
St Louis, Missouri, United States
Novartis Investigative Site
Great Falls, Montana, United States
Novartis Investigative Site
Voorhees Township, New Jersey, United States
Novartis Investigative Site
Durham, North Carolina, United States
Novartis Investigative Site
Antwerp, , Belgium
Novartis Investigative Site
Brussels, , Belgium
Novartis Investigative Site
Sint-Niklaas, , Belgium
Novartis Investigative Site
Aarhus, , Denmark
Novartis Investigative Site
Angers, , France
Novartis Investigative Site
Avignon, , France
Novartis Investigative Site
Bayonne, , France
Novartis Investigative Site
Besançon, , France
Novartis Investigative Site
Caen, , France
Novartis Investigative Site
Colmar, , France
Novartis Investigative Site
Dechy, , France
Novartis Investigative Site
Nancy, , France
Novartis Investigative Site
Paris, , France
Novartis Investigative Site
Reims, , France
Novartis Investigative Site
Reims, , France
Novartis Investigative Site
Saint-Grégoire, , France
Novartis Investigative Site
Saint-Priest-en-Jarez, , France
Novartis Investigative Site
Strasbourg, , France
Novartis Investigative Site
Vannes, , France
Novartis Investigative Site
Ravensburg, Baden-Wurttemberg, Germany
Novartis Investigative Site
Eggenfelden, Bavaria, Germany
Novartis Investigative Site
Fürth, Bavaria, Germany
Novartis Investigative Site
Landshut, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Munich, Bavaria, Germany
Novartis Investigative Site
Nuremberg, Bavaria, Germany
Novartis Investigative Site
Rosenheim, Bavaria, Germany
Novartis Investigative Site
Würzburg, Bavaria, Germany
Novartis Investigative Site
Potsdam, Brandenburg, Germany
Novartis Investigative Site
Frankfurt am Main, Hesse, Germany
Novartis Investigative Site
Wiesbaden, Hesse, Germany
Novartis Investigative Site
Bottrop, North Rhine-Westphalia, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Duisburg, North Rhine-Westphalia, Germany
Novartis Investigative Site
Goch, North Rhine-Westphalia, Germany
Novartis Investigative Site
Herne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Velbert, North Rhine-Westphalia, Germany
Novartis Investigative Site
Witten, North Rhine-Westphalia, Germany
Novartis Investigative Site
Würselen, North Rhine-Westphalia, Germany
Novartis Investigative Site
Mainz, Rhineland-Palatinate, Germany
Novartis Investigative Site
Speyer, Rhineland-Palatinate, Germany
Novartis Investigative Site
Halle, Saxony-Anhalt, Germany
Novartis Investigative Site
Lübeck, Schleswig-Holstein, Germany
Novartis Investigative Site
Berlin, , Germany
Novartis Investigative Site
Brandenburg, , Germany
Novartis Investigative Site
Bremen, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Hamburg, , Germany
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
Athens, , Greece
Novartis Investigative Site
N. Kifisia, Athens, , Greece
Novartis Investigative Site
Neo Faliro, , Greece
Novartis Investigative Site
Pátrai, , Greece
Novartis Investigative Site
Peiraius, , Greece
Novartis Investigative Site
Thessaloniki, , Greece
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Budapest, , Hungary
Novartis Investigative Site
Kaposvár, , Hungary
Novartis Investigative Site
Tatabánya, , Hungary
Novartis Investigative Site
Veszprém, , Hungary
Novartis Investigative Site
Bologna, Emilia-Romagna, Italy
Novartis Investigative Site
Bologna, Emilia-Romagna, Italy
Novartis Investigative Site
Meldola (FC), Emilia-Romagna, Italy
Novartis Investigative Site
Rimini, Emilia-Romagna, Italy
Novartis Investigative Site
Udine, Friuli Venezia Giulia, Italy
Novartis Investigative Site
Rome, Lazio, Italy
Novartis Investigative Site
Monza, Lombardy, Italy
Novartis Investigative Site
Treviglio (BG), Lombardy, Italy
Novartis Investigative Site
Novara, Piedmont, Italy
Novartis Investigative Site
Fermo (AP), The Marches, Italy
Novartis Investigative Site
Trento, Trentino-Alto Adige, Italy
Novartis Investigative Site
Lido Di Camaiore (LU), Tuscany, Italy
Novartis Investigative Site
Pisa, Tuscany, Italy
Novartis Investigative Site
Perugia, Umbria, Italy
Novartis Investigative Site
Varese, , Italy
Novartis Investigative Site
Bydgoszcz, , Poland
Novartis Investigative Site
Bytom, , Poland
Novartis Investigative Site
Gliwice, , Poland
Novartis Investigative Site
Konin, , Poland
Novartis Investigative Site
Lodz, , Poland
Novartis Investigative Site
Olsztyn, , Poland
Novartis Investigative Site
Rzeszów, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Wroclaw, , Poland
Novartis Investigative Site
Arkhangelsk, , Russia
Novartis Investigative Site
Chelyabinsk, , Russia
Novartis Investigative Site
Kazan', , Russia
Novartis Investigative Site
Kirov, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Moscow Region, , Russia
Novartis Investigative Site
Nizhny Novgorod, , Russia
Novartis Investigative Site
Obninsk, , Russia
Novartis Investigative Site
Petrozavodsk, , Russia
Novartis Investigative Site
Ryazan, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Saint Petersburg, , Russia
Novartis Investigative Site
Tver', , Russia
Novartis Investigative Site
Veliky Novgorod, , Russia
Novartis Investigative Site
Voronezh, , Russia
Novartis Investigative Site
Vsevolozhsk, , Russia
Novartis Investigative Site
A Coruña, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Barcelona, , Spain
Novartis Investigative Site
Cáceres, , Spain
Novartis Investigative Site
Hospitalet de Llobregat (Barcelona), , Spain
Novartis Investigative Site
Jerez (Cadiz), , Spain
Novartis Investigative Site
Lleida, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Málaga, , Spain
Novartis Investigative Site
Palma de Mallorca, , Spain
Novartis Investigative Site
Palma de Mallorca, , Spain
Novartis Investigative Site
Santiago de Compostela, , Spain
Novartis Investigative Site
Seville, , Spain
Novartis Investigative Site
Seville, , Spain
Novartis Investigative Site
Torrevieja (Alicante), , Spain
Novartis Investigative Site
Valencia, , Spain
Novartis Investigative Site
Stockholm, , Sweden
Novartis Investigative Site
Uppsala, , Sweden
Novartis Investigative Site
Vaxjo, , Sweden
Novartis Investigative Site
Västerås, , Sweden
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Bangkok, , Thailand
Novartis Investigative Site
Chiang Mai, , Thailand
Novartis Investigative Site
Songkhla, , Thailand
Novartis Investigative Site
Edinburgh, Midlothian, United Kingdom
Novartis Investigative Site
Birmingham, West Midlands, United Kingdom
Novartis Investigative Site
Aberdeen, , United Kingdom
Novartis Investigative Site
Burton-on-Trent, , United Kingdom
Novartis Investigative Site
Cottingham, Hull, , United Kingdom
Novartis Investigative Site
Huddersfield, , United Kingdom
Novartis Investigative Site
Ipswich, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
London, , United Kingdom
Novartis Investigative Site
Maidstone, , United Kingdom
Novartis Investigative Site
Nottingham, , United Kingdom
Novartis Investigative Site
Peterborough, , United Kingdom
Novartis Investigative Site
Sheffield, , United Kingdom
Novartis Investigative Site
Shrewsbury, , United Kingdom
Novartis Investigative Site
Southampton, , United Kingdom
Novartis Investigative Site
Wolverhampton, , United Kingdom
Novartis Investigative Site
Worthing, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111438
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.